

# CITATION REPORT

List of articles citing

## Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses

DOI: 10.1016/j.chom.2015.08.006  
Cell Host and Microbe, 2015, 18, 354-62.

**Source:** <https://exaly.com/paper-pdf/62657134/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| #  | Paper   | IF   | Citations |
|----|---|------|-----------|
| 62 | Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants. <i>Viruses</i> , <b>2015</b> , 7, 5443-75  | 6.2  | 20        |
| 61 | Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses. <i>PLoS Pathogens</i> , <b>2016</b> , 12, e1005817  | 7.6  | 89        |
| 60 | Humoral Immune Pressure Selects for HIV-1 CXCR4-chemokine Receptor 4-using Variants. <i>EBioMedicine</i> , <b>2016</b> , 8, 237-247   | 8.8  | 12        |
| 59 | Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection. <i>Nature Reviews Drug Discovery</i> , <b>2016</b> , 15, 823-834   | 64.1 | 41        |
| 58 | Resistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction. <i>Cell Host and Microbe</i> , <b>2016</b> , 20, 429-442   | 23.4 | 115       |
| 57 | Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies. <i>Cell Reports</i> , <b>2016</b> , 16, 2327-38  | 10.6 | 163       |
| 56 | Co-receptor Binding Site Antibodies Enable CD4-Mimetics to Expose Conserved Anti-cluster A ADCC Epitopes on HIV-1 Envelope Glycoproteins. <i>EBioMedicine</i> , <b>2016</b> , 12, 208-218                   | 8.8  | 45        |
| 55 | Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. <i>EBioMedicine</i> , <b>2016</b> , 12, 196-207   | 8.8  | 28        |
| 54 | Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity. <i>Journal of Virology</i> , <b>2016</b> , 90, 636-49           | 6.6  | 53        |
| 53 | HIV-Host Interactions: Implications for Vaccine Design. <i>Cell Host and Microbe</i> , <b>2016</b> , 19, 292-303  | 23.4 | 108       |
| 52 | Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller. <i>Science Translational Medicine</i> , <b>2017</b> , 9,                                | 17.5 | 96        |
| 51 | Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies. <i>Immunological Reviews</i> , <b>2017</b> , 275, 62-78   | 11.3 | 37        |
| 50 | Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development. <i>Immunological Reviews</i> , <b>2017</b> , 275, 145-160  | 11.3 | 102       |
| 49 | Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk. <i>Journal of Virology</i> , <b>2017</b> , 91, | 6.6  | 23        |
| 48 | Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System. <i>Current HIV/AIDS Reports</i> , <b>2017</b> , 14, 54-62   | 5.9  | 17        |
| 47 | Synthetic Three-Component HIV-1 V3 Glycopeptide Immunogens Induce Glycan-Dependent Antibody Responses. <i>Cell Chemical Biology</i> , <b>2017</b> , 24, 1513-1522.e4  | 8.2  | 30        |
| 46 | HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine. <i>Journal of Virology</i> , <b>2017</b> , 91,                              | 6.6  | 19        |

|    |   |      |    |
|----|---|------|----|
| 45 | Maternal Humoral Immune Correlates of Peripartum Transmission of Clade C HIV-1 in the Setting of Peripartum Antiretrovirals. <i>Vaccine Journal</i> , <b>2017</b> , 24,   |      | 11 |
| 44 | Model-robust inference for continuous threshold regression models. <i>Biometrics</i> , <b>2017</b> , 73, 452-462  | 1.8  | 16 |
| 43 | Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection. <i>Journal of Infectious Diseases</i> , <b>2017</b> , 215, S152-S159  | 7    | 17 |
| 42 | The Role of Maternal HIV Envelope-Specific Antibodies and Mother-to-Child Transmission Risk. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 1091   | 8.4  | 6  |
| 41 | Neutralization tiers of HIV-1. <i>Current Opinion in HIV and AIDS</i> , <b>2018</b> , 13, 128-136   | 4.2  | 53 |
| 40 | Development of a high-throughput bead based assay system to measure HIV-1 specific immune signatures in clinical samples. <i>Journal of Immunological Methods</i> , <b>2018</b> , 454, 48-58                          | 2.5  | 10 |
| 39 | HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis. <i>Journal of Virology</i> , <b>2018</b> , 92,  | 6.6  | 25 |
| 38 | Increased surface expression of HIV-1 envelope is associated with improved antibody response in vaccinia prime/protein boost immunization. <i>Virology</i> , <b>2018</b> , 514, 106-117                               | 3.6  | 12 |
| 37 | The Neutralizing Antibody Response to the HIV-1 Env Protein. <i>Current HIV Research</i> , <b>2018</b> , 16, 21-28  | 1.3  | 20 |
| 36 | Evolution of Neutralization Response in HIV-1 Subtype C-Infected Individuals Exhibiting Broad Cross-Clade Neutralization of HIV-1 Strains. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 618                      | 8.4  | 2  |
| 35 | Infant transmitted/founder HIV-1 viruses from peripartum transmission are neutralization resistant to paired maternal plasma. <i>PLoS Pathogens</i> , <b>2018</b> , 14, e1006944                                      | 7.6  | 19 |
| 34 | Novel vaccines: Technology and development. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 143, 844-851  | 11.5 | 4  |
| 33 | A New Family of Small-Molecule CD4-Mimetic Compounds Contacts Highly Conserved Aspartic Acid 368 of HIV-1 gp120 and Mediates Antibody-Dependent Cellular Cytotoxicity. <i>Journal of Virology</i> , <b>2019</b> , 93, | 6.6  | 11 |
| 32 | A Single Substitution in gp41 Modulates the Neutralization Profile of SHIV during In Vivo Adaptation. <i>Cell Reports</i> , <b>2019</b> , 27, 2593-2607.e5  | 10.6 | 7  |
| 31 | Antibody-Induced Internalization of HIV-1 Env Proteins Limits Surface Expression of the Closed Conformation of Env. <i>Journal of Virology</i> , <b>2019</b> , 93,  | 6.6  | 23 |
| 30 | Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 2741        | 8.4  | 14 |
| 29 | Two Families of Env Antibodies Efficiently Engage Fc-Gamma Receptors and Eliminate HIV-1-Infected Cells. <i>Journal of Virology</i> , <b>2019</b> , 93,   | 6.6  | 32 |
| 28 | Engineering antibody-based molecules for HIV treatment and cure. <i>Current Opinion in HIV and AIDS</i> , <b>2020</b> , 15, 290-299   | 4.2  | 2  |

|    |   |      |    |
|----|---|------|----|
| 27 | Diversity and Function of Maternal HIV-1-Specific Antibodies at the Time of Vertical Transmission. <i>Journal of Virology</i> , <b>2020</b> , 94,   | 6.6  | 2  |
| 26 | Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants. <i>MBio</i> , <b>2020</b> , 11,  | 7.8  | 15 |
| 25 | Induction of Neutralizing Responses against Autologous Virus in Maternal HIV Vaccine Trials. <i>MSphere</i> , <b>2020</b> , 5,  | 5    | 1  |
| 24 | Mutations that confer resistance to broadly-neutralizing antibodies define HIV-1 variants of transmitting mothers from that of non-transmitting mothers.  |      | 1  |
| 23 | Mutations that confer resistance to broadly-neutralizing antibodies define HIV-1 variants of transmitting mothers from that of non-transmitting mothers. <i>PLoS Pathogens</i> , <b>2021</b> , 17, e1009478 | 7.6  | 1  |
| 22 | Functional Anatomy of the Trimer Apex Reveals Key Hydrophobic Constraints That Maintain the HIV-1 Envelope Spike in a Closed State. <i>MBio</i> , <b>2021</b> , 12,   | 7.8  | 6  |
| 21 | SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. <i>Microorganisms</i> , <b>2021</b> , 9,   | 4.9  | 2  |
| 20 | Different evolutionary pathways of HIV-1 between fetus and mother perinatal transmission pairs indicate unique immune selection in fetuses. <i>Cell Reports Medicine</i> , <b>2021</b> , 2, 100315          | 18   | 0  |
| 19 | Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain.  |      | 0  |
| 18 | Elimination of SHIV Infected Cells by Combinations of Bispecific HIVxCD3 DART Molecules. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 710273  | 8.4  | 0  |
| 17 | Characterizing the Relationship Between Neutralization Sensitivity and Gene Diversity During ART Suppression. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 710327                                     | 8.4  | 2  |
| 16 | Tandem bispecific broadly neutralizing antibody - a novel approach to HIV-1 treatment. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 2189-2191  | 15.9 | 1  |
| 15 | Antigenic characterization of the human immunodeficiency virus (HIV-1) envelope glycoprotein precursor incorporated into nanodiscs. <i>PLoS ONE</i> , <b>2017</b> , 12, e0170672                            | 3.7  | 6  |
| 14 | Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. <i>PLoS Pathogens</i> , <b>2016</b> , 12, e1005742               | 7.6  | 61 |
| 13 | The Impact of IgG transplacental transfer on early life immunity. <i>ImmunoHorizons</i> , <b>2018</b> , 2, 14-25  | 2.7  | 96 |
| 12 | To bnAb or Not to bnAb: Defining Broadly Neutralising Antibodies Against HIV-1. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 708227   | 8.4  | 2  |
| 11 | Infant Transmitted/Founder HIV-1 Viruses from Peripartum Transmission are Neutralization Resistant to Paired Maternal Plasma.   |      | 1  |
| 10 | Development of a high-throughput bead based assay system to measure HIV-1 specific immune signatures in clinical samples.   |      |    |

- 9 Diversity and function of maternal HIV-1-specific antibodies at the time of vertical transmission.
- 8 Maternal alum-adjuvanted recombinant HIV Env vaccine does not enhance autologous virus neutralization in HIV-infected pregnant women.
- 7 Different evolutionary pathways of HIV-1 between fetus and mother perinatal transmission pairs indicate unique immune selection pressure in fetuses.
- 6 Anti-HIV antibody development up to one year after antiretroviral therapy initiation in acute HIV infection. *Journal of Clinical Investigation*, **2021**, 15.9 1
- 5 data\_sheet\_1.DOCX. **2018**,
- 4 Presentation\_1.pdf. **2019**,
- 3 Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain.. *Science Advances*, **2022**, 8, eabm3948 14.3
- 2 Impact of adjuvants on the biophysical and functional characteristics of HIV vaccine-elicited antibodies in humans. **2022**, 7,
- 1 A calculated risk: Evaluating HIV resistance to the broadly neutralising antibodies10-1074 and 3BNC117. **2022**, 17, 352-358 0